Images List Premium Download Classic

Monoclonal

Monoclonal-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (igf-1)
The University Of North Carolina At Chapel Hill
January 18, 2018 - N°20180016340

The present invention provides an antibody or antigen-binding fragment thereof that binds αvβ3 integrin, as well as methods of use in the treatment of diseases and disorders.
NEW Soluble mic neutralizing monoclonal antibody for treating cancer
University Of Washington Through Its Center For Commercialization
January 18, 2018 - N°20180016339

Described herein are compositions and methods relating to antibodies that bind soluble mic (smic), e. G. For the treatment of mic-positive cancers.
NEW Antibodies specific for hyperphosphorylated tau and methods of use thereof
H. Lundbeck A/s
January 18, 2018 - N°20180016330

The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (phf) tau (ps396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of alzheimer's disease and other tauopathies.
NEW Monoclonal Patent Pack
Download 358+ patent application PDFs
Monoclonal Patent Applications
Download 358+ Monoclonal-related PDFs
For professional research & prior art discovery
inventor
  • 358+ full patent PDF documents of Monoclonal-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
NEW Antibodies that bind human c6 and uses thereof
Regenesance B.v.
January 18, 2018 - N°20180015162

Isolated monoclonal antibodies that bind to human complement component c6 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic methods for using the antibodies.
Monoclonal antibody for the diagnosis, treatment and/or prevention of brain tumors and brain lesions
Consejo Superior De Investigaciones Cientificas (csic)
January 11, 2018 - N°20180011095

The invention relates to the use of the monoclonal antibody nilo1 for the diagnosis, treatment and/or prevention of brain tumors and lesions. Particularly, the invention relates to methods for the diagnosis of brain tumors and brain lesions in which cells marked with said antibody, or with immunologically active fragments thereof, are detected. The invention also relates to the use ...
Method for producing monoclonal iga antibody
Cured Inc.
January 11, 2018 - N°20180009906

The present invention provides a component having effects in vivo of improving or optimizing the intestinal environment, suppressing intestinal putrefaction, or suppressing alternation of intestinal bacterial growth and/or pathological changes of intestinal bacterial growth in gut microbiota. The invention also provides an active ingredient suitably used for treating intestinal diseases. The invention provides a monoclonal iga antibody that binds ...
Monoclonal Patent Pack
Download 358+ patent application PDFs
Monoclonal Patent Applications
Download 358+ Monoclonal-related PDFs
For professional research & prior art discovery
inventor
  • 358+ full patent PDF documents of Monoclonal-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Human monoclonal antibodies endowed with strong neutralizing activity against hsv-1 and hsv-2
Polichem S.a.
January 11, 2018 - N°20180009879

The present invention is in the field of monoclonal antibodies suitable for passive immunotherapy of herpes simplex virus infections and relates to human monoclonal antibodies or fragments of said antibodies, which bind and neutralize hsv-1 and hsv-2, and their use in the prophylaxis or treatment of hsv-1 or hsv-2-associated diseases.
Modulation of charge variants in a monoclonal antibody composition
Oncobiologics, Inc.
January 11, 2018 - N°20180009876

Combinations of different chromatography modalities with particularly refined conditions significantly reduce acid charge variants in a preparation of monoclonal antibodies. The process for reducing acid charge variants utilizes a combination of anion exchange and hydrophobic interaction chromatography, followed by cation exchange chromatography polishing, whereby the levels of acidic or basic charge species of the monoclonal antibodies may be modulated to ...
A method for producing a recombinant allotypespecific rabbit monoclonal antibody
Abcam Plc
January 11, 2018 - N°20180009875

A method for cloning a full length coding sequence for a light chain of a rabbit monoclonal antibody is provided. In some embodiments, this method may involve: fusing a b cell from a rabbit having a b4 allotype with a 240e cell or a derivative thereof to produce a hybridoma, wherein the b cell and the hybridoma produce a monoclonal ...
Stable liquid formulation for monoclonal antibodies
Sanofi
January 11, 2018 - N°20180008707

The present invention concerns stable pharmaceutical compositions for monoclonal antibodies, for example igg antibodies. The invention further relates to medicaments and treatments using the pharmaceutical compositions of the invention. Additionally, the invention relates to a kit comprising at least one of the pharmaceutical compositions of the invention and a method for reducing aggregation of antibodies.
Monoclonal antibodies with enhanced adcc function
Laboratoire Francais Du Fractionnement Et Des Biotechnologies
January 04, 2018 - N°20180002442

The invention concerns a method for obtaining and selecting monoclonal antibodies by an addc-type test, said antibodies capable of activating type iii fcy receptors and having a particular glycan structure. The inventive anti-d antibodies can be used for preventing rhesus isoimmunisation in rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic ...
Humanized anti-trop-2 monoclonal antibodies and uses thereof
Abruzzo Theranostic S.r.l.
January 04, 2018 - N°20180002437

The present invention refers to humanized anti-trop-2 antibodies and their fragments, derivatives and conjugates that are able to recognise and bind with high affinity distinct regions of the trop-2 molecule. The present invention also teaches the use of such antibodies and of pharmaceutical compositions thereof for diagnosis and therapy of human pathologies, in particular cancer.
Human monoclonal antibodies against orexin receptor type 1
Universite De Montpellier
January 04, 2018 - N°20180002421

The present disclosure relates to human monoclonal antibodies against orexin receptor type 1 (ox1r, hyprocretin 1) and uses thereof for the treatment of cancer. The antibodies are characterized by their cdrs: nyymn, yisgssrniyyadfvkg, snydgmdv (heavy chain) and agtssdvggsnyvs, pgkap, ssytyystrv (light chain)) or the cdrs having at least 50% or 70% identity with the above listed sequences.
Monoclonal Patent Pack
Download 358+ patent application PDFs
Monoclonal Patent Applications
Download 358+ Monoclonal-related PDFs
For professional research & prior art discovery
inventor
  • 358+ full patent PDF documents of Monoclonal-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Neutralizing gp41 antibodies and their use
The United States Of America, As Represented By The Secretary, Department Of Health And Human
January 04, 2018 - N°20180002406

Monoclonal neutralizing antibodies are disclosed that specifically bind to the hiv-1 gp41 membrane-proximal external region (mper). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the ...
Cd33 specific chimeric antigen receptors
Intrexon Corporation
January 04, 2018 - N°20180002397

Provided herein are chimeric antigen receptors (cars) for cancer therapy, and more particularly, cars containing a scfv from a cd33 monoclonal antibody. Provided are immune effector cells containing such cars, and methods of treating proliferative disorders such as acute myeloid leukemia (aml), and relapsed or refractory aml.
Anti-hsp70 specific chimeric antigen receptors (cars) for cancer immunotherapy
Cellectis
January 04, 2018 - N°20180000914

The present invention relates to chimeric antigen receptors (car) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scfv derived from an anti-hsp70 monoclonal antibody, conferring specific immunity against hsp70 positive cells. The engineered immune cells endowed with such cars are particularly ...
New markers for early diagnosis of ovarian cancer, monitoring during therapy, and new therapy options ...
Bioventures, Llc
December 28, 2017 - N°20170369926

The inventors have identified several proteases and a protease inhibitor that are overexpressed in ovarian cancer tumors. They have developed monoclonal antibodies against the proteins and shown that they can be detected in serum and the levels of the proteins in serum fluctuate during cancer treatment. They have shown that serum assays for the proteases and protease inhibitor can be ...
Zcytor17 heterodimeric cytokine receptor monoclonal antibodies
Zymogenetics, Inc.
December 28, 2017 - N°20170369580

Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods ...
Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv ...
Ubi Us Holdings, Llc.
December 28, 2017 - N°20170369576

The present disclosure is directed to compositions and methods for the prevention, treatment, and/or functional cure of hiv infection. One aspect of the present disclosure relates to monoclonal antibodies directed against cd4, compositions thereof, and methods employing such compositions for the prevention, treatment, and functional cure of hiv infection.
Interferon alpha antibodies and their uses
E. R. Squibb & Sons, L.l.c.
December 28, 2017 - N°20170369568

The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (ifn) alpha subtypes but do not substantially inhibit the biological activity of ifn alpha 21 or the biological activity of either ifn beta or ifn omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also ...
Neutralizing antibodies to hiv-1 and their use
University Of Washington
December 28, 2017 - N°20170369558

Monoclonal neutralizing antibodies are disclosed that specifically bind to the cd4 binding site of hiv-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to hiv-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.
Loading